ADAMTS13 activity and inhibitor

American Journal of Hematology

Volumn 83, Issue 10, 2008, Pages 811-814

  Doldan Silvero, Adriana ^a   Acevedo Gadea, Carlos ^a   Habib, Clandine ^a   Freeman, Jonathan ^a   Johari, Vandita ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; RELAPSE; RISK ASSESSMENT; TECHNIQUE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENES, RECESSIVE; HETEROZYGOTE; HOMOZYGOTE; HORSERADISH PEROXIDASE; HUMANS; MOLECULAR WEIGHT; MUTATION; PLASMA EXCHANGE; PROTEIN STRUCTURE, TERTIARY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 53549121713     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21257     Document Type: Article

References (32)

1. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-1675.
2. Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666.
3. Zheng X, Chung D, Takayama T, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS 13), a metalloprotease involved in TTP. J Biol Chem 2001;276: 41059-41063.
4. Peyvandi F, Lavoretano S, Palla R, et al. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 2006;27:330-336.
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute TTP. N Engl J Med 1998;339:1585-1594.
6. Rieger M, Manuccio PM, Kremer Hovinga JA, et al. ADAMTS 13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005;106:1262-1267.
7. Furlan M, Robles R, Lamie B, et al. Partial purification and characterization of a protease from human plasma cleaving vonWillebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-4234.
8. Tsai H-M. Physiologic cleavage of vonWillebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244.
9. Gerritsen H, Turecek P, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999;82:1380-1381.
10. Bohm M, Vigh T, Scharrer I, et al. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002;81:430-435.
11. Whitelock JL, Nolasco L, Bernardo A, et al. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004;2:485-491.
12. Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 2004;91:806-811.
13. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS 13 assay. Br J Haematol 2005;129:93-100.
14. Meyer SC, Sulzer I, Lamie B, et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement byFRETS-VWF73 assay: Diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007;5:866-867.
15. Wu JJ, Fujikawa K, Lian EC, et al. A rapid enzyme-linked assay for ADAMTS-13. J Thromb Haemost 2006;4:129-136.
16. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049.
17. Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTSI3) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004;44:146-150.
18. Vesely SK, George IN, Lammle B, et al. ADAMTS 13 activity in TTP-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
19. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006;107:528-534.
20. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol 2007; published online.
21. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTR Blood 2003;101:1845-1850.
22. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS 13 antibodies as markers for recurrence of acquired TTP during remission. Haematologica 2008;93:232-239.
23. Mori Y, Wada H, Gabazza E, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002;42:572-580.
24. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory of anti-ADAMTS 13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006;132:66-74.
25. Knovich MA, Lawson HL, et al. Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: Clinical applications and comparison with immunoblot method. Am J Hematol 2008;83:654-656.
26. Boctor FN, Smith JA. Diagnosis of thrombotic thrombocytopenic purpura with normal ADAMTS13 activity and absence of its inhibitor (anti-ADAMTS13 antibodies). Am J Hematol 2008;83:256.
27. Whitlatch NL, Martin MG, Shah BD, et al. Response to Boctor and Smith. Am J Hematol 2008;83:256.
28. Whitlatch NL, Martin MG, Shah BD, et al. Thrombotic thrombocytopenic purpura induced by thrimethoprin-sulfanethoxazole in a Jehovah's Witness. Am J Hematol 2007;82:679-681.
29. Werner TL, Agarwal N, Carney HM, et al. Management of cancer-associated thrombotic microangiopathy: What is the right approach? Am J Hematol 2007;82:295-298.
30. Cataland SR, Jin M, Wu HM. Rapid determination of ADAMTS13 activity improves clinical decision-making. Am J Hematol 2007;82:251.
31. Schnog JJB, Kremer Hovinga JA, Krieg S, et al. ADAMTS13 activity in sickle cell disease. Am J Hematol 2006;81492-498.
32. Martinez Outschoom U, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: A retrospective cohort study. Am J Hematol 2006;81:895-900.